Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOHEMIA phase III trial of ivermectin mass drug administration for malaria prevention
PACTR202106695877303Phase 3Completed
- Sponsor
- Barcelona Institute for Global Health
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ivermectin and albendazole in malaria (3 arms), sponsored by Barcelona Institute for Global Health. Primary endpoint: Safety and efficacy of ivermectin mass drug administration for malaria prevention. Started Jan 2022; status: completed.
02
Drugs
ivermectinalbendazole
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202106695877303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106695877303.